Cyclin-Dependent Kinase Synthetic Lethality Partners in DNA Damage Response

Cyclin-dependent kinases in DNA damage response

(2022) Mateusz Kciuk et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Capitalizing on Synthetic Lethality of MYC to Treat Cancer in the Digital Age

(2021) Dexter Kai Hao Thng et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

The Interactions of DNA Repair, Telomere Homeostasis, and p53 Mutational Status in Solid Cancers: Risk, Prognosis, and Prediction

(2021) Pavel Vodicka et al.   Cancers

Targeting “undruggable” c-Myc protein by synthetic lethality

(2021) Chen Wang et al.   Frontiers of Medicine

Targeting CDK9 for Anti-Cancer Therapeutics

(2021) Ranadip Mandal et al.   Cancers

Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials

(2021) E. Panagiotou et al.   Clinical & Translational Oncology

Cyclin-dependent kinase inhibitors (CDKIs) and the DNA damage response: The link between signaling pathways and cancer

(2021) Jafar Amani et al.   DNA REPAIR

Cyclin-Dependent Kinase Inhibitors and Their Therapeutic Potential in Colorectal Cancer Treatment

(2021) Oana-Maria Thoma et al.   Frontiers in Pharmacology

Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer

(2020) Feiyue Zheng et al.   BIOMEDICINE & PHARMACOTHERAPY

CDK7 inhibitors as anticancer drugs

(2020) Georgina P. Sava et al.   CANCER AND METASTASIS REVIEWS

MYC and the unfolded protein response in cancer: synthetic lethal partners in crime?

(2020) Tingting Zhang et al.   EMBO Molecular Medicine

Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation

(2020) Win Topatana et al.   Journal of Hematology & Oncology

Poly(ADP-ribose) polymerase inhibition: past, present and future

(2020) Nicola J. Curtin et al.   NATURE REVIEWS DRUG DISCOVERY

The promise and current status of CDK12/13 inhibition for the treatment of cancer

(2020) Solomon Tadesse et al.   Future Medicinal Chemistry

PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy

(2019) Arash Salmaninejad et al.   JOURNAL OF CELLULAR PHYSIOLOGY

p53 and its isoforms in DNA double-stranded break repair

(2019) Yu-xi Zhang et al.   Journal of Zhejiang University-SCIENCE B

Cyclin-dependent kinase-9 is a therapeutic target in MYC-expressing diffuse large B-cell lymphoma

(2019) Taylor Hashiguchi et al.   MOLECULAR CANCER THERAPEUTICS

CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation

(2019) Malgorzata Krajewska et al.   Nature Communications

Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers

(2019) Jarosław Przybycinski et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Mechanisms of Oncogene-Induced Replication Stress: Jigsaw Falling into Place

(2018) Panagiotis Kotsantis et al.   Cancer Discovery

CDK12: an emerging therapeutic target for cancer

(2018) Goldie Y L Lui et al.   JOURNAL OF CLINICAL PATHOLOGY

Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors

(2017) Sampada Kalan et al.   Cell Reports

Cdk2 strengthens the intra-S checkpoint and counteracts cell cycle exit induced by DNA damage

(2017) Katarina Bačević et al.   Scientific Reports

Silencing of CDK2, but not CDK1, separates mitogenic from anti-apoptotic signaling, sensitizing p53 defective cells for synthetic lethality

(2016) Tatyana S. Nekova et al.   CELL CYCLE

Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer

(2016) N. A. Jabbour-Leung et al.   MOLECULAR CANCER THERAPEUTICS

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer

(2016) Shawn F. Johnson et al.   Cell Reports

p53 in the DNA-Damage-Repair Process

(2016) Ashley B. Williams et al.   Cold Spring Harbor Perspectives in Medicine

The Werner syndrome protein: linking the replication checkpoint response to genome stability

(2016) Pietro Pichierri et al.   Aging-US

Myc and cell cycle control

(2015) Gabriel Bretones et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

The MRN complex is transcriptionally regulated by MYCN during neural cell proliferation to control replication stress

(2015) M Petroni et al.   CELL DEATH AND DIFFERENTIATION

A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition

(2015) D. A. Alagpulinsa et al.   MOLECULAR CANCER THERAPEUTICS

MYC, Metabolism, and Cancer

(2015) Z. E. Stine et al.   Cancer Discovery

CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo

(2015) G P Gregory et al.   LEUKEMIA

Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells

(2014) Jian Kang et al.   BMC CANCER

CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer

(2014) Edmond Chipumuro et al.   CELL

Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells

(2014) Sudha Mannava et al.   CELL CYCLE

Synthetic Lethal Screens as a Means to Understand and Treat MYC-Driven Cancers

(2014) S. Cermelli et al.   Cold Spring Harbor Perspectives in Medicine

The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition

(2013) QING XIA et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers

(2013) M. Pourdehnad et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

(2013) Alexandre Puissant et al.   Cancer Discovery

Cdc45 Is a Critical Effector of Myc-Dependent DNA Replication Stress

(2013) Seetha V. Srinivasan et al.   Cell Reports

MYC on the Path to Cancer

(2012) Chi V. Dang   CELL

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition

(2012) Dai Horiuchi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma

(2012) C. K. Cheng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Functional genomics identifies therapeutic targets for MYC-driven cancer

(2012) M. Toyoshima et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic

(2011) Timothy A. Yap et al.   CA-A CANCER JOURNAL FOR CLINICIANS

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Nucleotide Deficiency Promotes Genomic Instability in Early Stages of Cancer Development

(2011) Assaf C. Bester et al.   CELL

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition

(2011) Neil Johnson et al.   NATURE MEDICINE

Targeting MYC dependence in cancer by inhibiting BET bromodomains

(2011) J. A. Mertz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability

(2011) A. Aly et al.   Journal of Molecular Cell Biology

Tumor Cell Kill by c-MYC Depletion: Role of MYC-Regulated Genes that Control DNA Double-Strand Break Repair

(2010) K. R. Luoto et al.   CANCER RESEARCH

Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor–chemotherapy combinations as an anticancer strategy for solid tumors

(2010) Neil Johnson et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Cdk2 suppresses cellular senescence induced by the c-myc oncogene

(2009) Stefano Campaner et al.   NATURE CELL BIOLOGY

c-Myc Accelerates S-Phase and Requires WRN to Avoid Replication Stress

(2009) Kristin Robinson et al.   PLoS One

Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells

(2009) J. J. Molenaar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Crosstalk between histone modifications during the DNA damage response

(2009) Haico van Attikum et al.   TRENDS IN CELL BIOLOGY

Replication fork stalling in WRN-deficient cells is overcome by prompt activation of a MUS81-dependent pathway

(2008) Annapaola Franchitto et al.   JOURNAL OF CELL BIOLOGY

Global Regulation of Nucleotide Biosynthetic Genes by c-Myc

(2008) Yen-Chun Liu et al.   PLoS One